Dendritic cell hyperactivation (hDC) platform, inflammasomes

Corner Therapeutics is pioneering a new paradigm in immunotherapy by focusing on the generation of long-lasting immunity through the activation of dendritic cells (DCs). These cells are crucial regulators of the immune system, capable of detecting threats such as cancer and infections. The company’s technology enhances the intelligence and functionality of DCs, enabling them to effectively stimulate T cell responses. By improving the processes of antigen uptake and presentation, co-stimulation, and cytokine secretion, Corner Therapeutics aims to induce durable memory T cells and robust antibody responses, which are essential for long-term protection against diseases.

The company’s platform represents a novel class of multi-purpose immunotherapies that target the core mechanisms of the immune system. By ensuring that DCs perform critical functions—such as migrating to lymph nodes, providing memory-inducing signals, and maintaining their viability—Corner Therapeutics seeks to overcome the limitations of existing immunotherapies that often fail to generate lasting immune responses. Their approach not only aims to treat a wide range of cancers and infectious diseases but also aspires to provide lifelong protective immunity, thereby addressing significant gaps in current therapeutic strategies.

United States

Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.

Corner Therapeutics

Company Details